Ecolab Inc. ECL
We take great care to ensure that the data presented and summarized in this overview for ECOLAB INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ECL
View all-
Vanguard Group Inc Valley Forge, PA23.5MShares$5.49 Billion0.11% of portfolio
-
Black Rock Inc. New York, NY20.9MShares$4.89 Billion0.11% of portfolio
-
State Street Corp Boston, MA11.5MShares$2.68 Billion0.12% of portfolio
-
Wellington Management Group LLP Boston, MA6.67MShares$1.56 Billion0.28% of portfolio
-
Morgan Stanley New York, NY5.95MShares$1.39 Billion0.11% of portfolio
-
Bill Gates Bill & Melinda Gates Foundation Trust | Kirkland, Wa5.22MShares$1.22 Billion2.63% of portfolio
-
Geode Capital Management, LLC Boston, MA4.98MShares$1.16 Billion0.11% of portfolio
-
Aristotle Capital Management, LLC Los Angeles, CA4.75MShares$1.11 Billion2.16% of portfolio
-
Pictet Asset Management Sa Geneva 73, V84.25MShares$993 Million0.95% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V84.01MShares$937 Million1.03% of portfolio
Latest Institutional Activity in ECL
Top Purchases
Top Sells
About ECL
Ecolab Inc. provides water, hygiene, and infection prevention solutions and services in the United States and internationally. The company operates through Global Industrial, Global Institutional & Specialty, and Global Healthcare & Life Sciences segments. The Global Industrial segment offers water treatment and process applications, and cleaning and sanitizing solutions to manufacturing, food and beverage processing, transportation, chemical, metals and mining, power generation, pulp and paper, commercial laundry, petroleum, refining, and petrochemical industries. The Global Institutional & Specialty segment provides specialized cleaning and sanitizing products to the foodservice, hospitality, lodging, government and education, and retail industries. Its Global Healthcare & Life Sciences segment offers specialized cleaning and sanitizing products to the healthcare, personal care, and pharmaceutical industries, such as infection prevention and surgical solutions, and end-to-end cleaning and contamination control solutions under the Ecolab, Microtek, and Anios brand names. The company's Other segment offers pest elimination services to detect, eliminate, and prevent pests, such as rodents and insects in restaurants, food and beverage processors, educational and healthcare facilities, hotels, quick service restaurant and grocery operations, and other institutional and commercial customers. This segment also provides colloidal silica for binding and polishing applications in semiconductor, catalyst, and aerospace component manufacturing, as well as chemical industries; and products and services that manage wash process through custom designed programs, premium products, dispensing equipment, water and energy management, and reduction, as well as real time data management. It sells its products through field sales and corporate account personnel, distributors, and dealers. The company was founded in 1923 and is headquartered in Saint Paul, Minnesota.
Insider Transactions at ECL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 06
2024
|
Arthur J Higgins |
SELL
Open market or private sale
|
Direct |
4,500
-14.98%
|
$1,021,500
$227.52 P/Share
|
May 06
2024
|
Arthur J Higgins |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+7.23%
|
$508,500
$113.92 P/Share
|
May 03
2024
|
David Mac Lennan |
BUY
Open market or private purchase
|
Direct |
650
+3.66%
|
$147,550
$227.37 P/Share
|
Mar 31
2024
|
John J Zillmer |
BUY
Grant, award, or other acquisition
|
Direct |
146
+0.32%
|
-
|
Mar 31
2024
|
Victoria Reich |
BUY
Grant, award, or other acquisition
|
Direct |
146
+0.61%
|
-
|
Mar 31
2024
|
Suzanne M Vautrinot |
BUY
Grant, award, or other acquisition
|
Direct |
146
+1.56%
|
-
|
Mar 31
2024
|
Tracy B Mc Kibben |
BUY
Grant, award, or other acquisition
|
Direct |
146
+1.71%
|
-
|
Mar 31
2024
|
Lionel L Nowell Iii |
BUY
Grant, award, or other acquisition
|
Direct |
146
+2.61%
|
-
|
Mar 31
2024
|
Michael Larson |
BUY
Grant, award, or other acquisition
|
Direct |
146
+0.95%
|
-
|
Mar 31
2024
|
David Mac Lennan |
BUY
Grant, award, or other acquisition
|
Direct |
198
+0.6%
|
$22,770
$115.4 P/Share
|
Mar 31
2024
|
Eric Mark Green |
BUY
Grant, award, or other acquisition
|
Direct |
281
+7.89%
|
$32,315
$115.4 P/Share
|
Mar 31
2024
|
Arthur J Higgins |
BUY
Grant, award, or other acquisition
|
Direct |
281
+0.55%
|
$32,315
$115.4 P/Share
|
Mar 31
2024
|
Shari L Ballard |
BUY
Grant, award, or other acquisition
|
Direct |
292
+2.04%
|
$33,580
$115.4 P/Share
|
Mar 31
2024
|
Barbara Beck |
BUY
Grant, award, or other acquisition
|
Direct |
303
+0.46%
|
$34,845
$115.4 P/Share
|
Mar 31
2024
|
Judson Althoff |
BUY
Grant, award, or other acquisition
|
Direct |
64
+50.0%
|
-
|
Mar 15
2024
|
Angela M Busch EVP - CORP STRAT & BUS DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
4,384
-20.61%
|
$982,016
$224.89 P/Share
|
Mar 15
2024
|
Angela M Busch EVP - CORP STRAT & BUS DEV |
BUY
Exercise of conversion of derivative security
|
Direct |
6,118
+22.34%
|
$654,626
$107.69 P/Share
|
Mar 15
2024
|
Suzanne M Vautrinot |
SELL
Payment of exercise price or tax liability
|
Direct |
1,351
-6.91%
|
$302,624
$224.89 P/Share
|
Mar 15
2024
|
Suzanne M Vautrinot |
BUY
Exercise of conversion of derivative security
|
Direct |
2,900
+12.32%
|
$301,600
$104.85 P/Share
|
Mar 14
2024
|
Michael Larson |
SELL
Payment of exercise price or tax liability
|
Direct |
1,119
-6.94%
|
$250,656
$224.75 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 42K shares |
---|---|
Exercise of conversion of derivative security | 84.6K shares |
Open market or private purchase | 2.8K shares |
Payment of exercise price or tax liability | 27.5K shares |
---|---|
Open market or private sale | 59.6K shares |
Discretionary transaction | 1.49K shares |